(Q34302240)

1 August 2017

1 reference

title

mTOR inhibitors: an overview (English)

1 reference

1 August 2017

1

Neuhaus P

1 reference

1 August 2017

Klupp J

2

1 reference

PubMed ID

11443573

1 August 2017

Langrehr JM

series ordinal

3

1 reference

1 August 2017

1 June 2001

1 reference

1 August 2017

Liver Transplantation

1 reference

1 August 2017

7

1 reference

1 August 2017

473-484

1 reference

1 August 2017

6

1 reference

Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle

1 August 2017

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.24645

Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.24645

Targets for Cell Cycle Arrest by the Immunosuppressant Rapamycin in Yeast

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.24645

Mammalian target of rapamycin: immunosuppressive drugs uncover a novel pathway of cytokine receptor signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.24645

Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.24645

A signaling pathway to translational control

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.24645

RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.24645

RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.24645

RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.24645

Immunopharmacology of rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.24645

The impact of immunosuppressive drugs on the analysis of T cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.24645

Rapamycin suppresses 5'TOP mRNA translation through inhibition of p70s6k.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.24645

3-Phosphoinositide-dependent protein kinase 1 (PDK1) phosphorylates and activates the p70 S6 kinase in vivo and in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.24645

Ribosomal S6 kinase signaling and the control of translation

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.24645

Immunophilins: beyond immunosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.24645

SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.24645

In vitro and in situ absorption of SDZ-RAD using a human intestinal cell line (Caco-2) and a single pass perfusion model in rats: comparison with rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.24645

The in vivo effect of rapamycin derivative SDZ RAD on lymphocyte proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.24645

Antiproliferative effect of rapamycin on growth factor-stimulated human adult lung fibroblasts in vitro may explain its superior efficacy for prevention and treatment of allograft obliterative airway disease in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.24645

Rapamycin inhibits hepatic stellate cell proliferation in vitro and limits fibrogenesis in an in vivo model of liver fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.24645

Rapamycin inhibits development of obliterative airway disease in a murine heterotopic airway transplant model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.24645

Donor T cells are not required for induction of allograft tolerance in mice treated with antilymphocyte serum, rapamycin, and donor bone marrow cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.24645

Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.24645

Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.24645

Suppression of acute rejection in allogeneic rat lung transplantation: a study of the efficacy and pharmacokinetics of rapamycin derivative (SDZ RAD) used alone and in combination with a microemulsion formulation of cyclosporine

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.24645

Successful treatment of acute, ongoing rat lung allograft rejection with the novel immunosuppressant SDZ-RAD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.24645

Coadministration of neoral and the novel rapamycin analog, SDZ RAD, to rat lung allograft recipients: potentiation of immunosuppressive efficacy and improvement of tolerability of staggered versus simultaneous treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.24645

Prevention of acute allograft rejection in nonhuman primate lung transplant recipients: induction with chimeric anti-interleukin-2 receptor monoclonal antibody improves the tolerability and potentiates the immunosuppressive activity of a regimen usi

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.24645

Combined immunosuppression with cyclosporine (neoral) and SDZ RAD in non-human primate lung transplantation: systematic pharmacokinetic-based trials to improve efficacy and tolerability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.24645

The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: A potential approach to prevention and treatment of posttransplant lymphoproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.24645

Comparison of acute rapamycin nephrotoxicity with cyclosporine and FK506.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.24645

Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.24645

Entry-into-human study with the novel immunosuppressant SDZ RAD in stable renal transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.24645

Requirements for therapeutic drug monitoring of sirolimus, an immunosuppressive agent used in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.24645

Toxicity and efficacy of sirolimus: relationship to whole-blood concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.24645

Advances in therapeutic drug monitoring for immunosuppressants: a review of sirolimus. Introduction and overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.24645

Therapeutic drug monitoring of immunosuppressant drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.24645

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.24645

Pharmacodynamics of immunosuppressive drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.24645

A phase I study of a 4-week course of SDZ-RAD (RAD) quiescent cyclosporine-prednisone-treated renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.24645

Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.24645

Sirolimus-induced thrombocytopenia and leukopenia in renal transplant recipients: risk factors, incidence, progression, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.24645

Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.24645

Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.24645

Potential utility of rapamycin and tacrolimus in long-term, low-toxicity regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.24645

International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.24645

Sirolimus in pediatric gastrointestinal transplantation: the use of sirolimus for pediatric transplant patients with tacrolimus-related cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.24645

Stratifying the patient at risk from coronary disease: new insights from the Framingham Heart Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.24645

Transplantation tolerance-where do we stand?

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.24645

Rapamune® (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.24645

Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1053%2FJLTS.2001.24645

21 January 2018

Identifiers

DOI

10.1053/JLTS.2001.24645

1 reference

1 August 2017

1 reference

PubMed ID

11443573